Stay updated with breaking news from Rob Iannone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jazz Pharmaceuticals is paying Zymeworks $50 million up front for rights to develop zanidatamab, a bispecific antibody cancer currently in two pivotal clinical trials. It’s the second bispecific antibody pact of the week, following Gilead Sciences’ deal to secure an option on a MacroGenics drug in early clinical development.
Epidiolex may ease symptoms associated with Doose syndrome, a rarer type of childhood-onset epilepsy - News - PharmaTimes
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced it has initiated a new Phase 3 trial to investigate the efficacy and safety of...
Topline results were announced from a phase 3 trial evaluating nabiximols oromucosal spray on clinical measures of spasticity in MS.
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 RELEASE MSS1 trial (NCT04657666) evaluating...